|
|
|||||||||||
Hugh Series is a consultant in the psychiatry of old age with Oxfordshire Mental Healthcare NHS Trust, working at the Warneford Hospital (Warneford Lane, Oxford OX3 7JX, UK. Tel./fax: 01865 226263; e-mail: hugh.series{at}oxmhc-tr.nhs.uk). His research interests include the neurochemistry of the serotonergic system. Pilar Dégano is a clinical pharmacist, also at the Warneford Hospital.
| Abstract |
|---|
|
|
|---|
Mr A, aged 83, presented at an accident and emergency department, where he was verbally abusive and physically aggressive. A mild cognitive impairment was noted and he was admitted to the psychiatric hospital under section 2 of the Mental Health Act 1983. Episodes of aggression, although not sexual behaviour, continued. After 6 months in hospital he was discharged under guardianship to a residential home, where he would sometimes threaten people with his stick. He always refused all medication. Four years later the aggression had worsened and he was readmitted to the general hospital with an infection, and transferred on section back to the psychiatric hospital. By this time his cognitive impairment had progressed and a diagnosis of dementia was made. Further aggression occurred on the ward. Several months later he was discharged to a nursing home, still refusing medication.In the home he now began to approach a female resident with sexual suggestions. Initially the staff managed this by moving him to a different floor, but the behaviour continued with other residents and he was readmitted to hospital because of the difficulty of managing it. On the first day in hospital he began to initiate sexually inappropriate behaviour with female patients who themselves had dementia. He became angry and threatening if staff intervened, for example to ask him to return to his room. He would also hit other patients with his stick if angry. Behavioural strategies were tried with only very limited success. Eventually the team came to the view that the level of risk to others was unacceptable despite the behavioural measures used, and he was detained under the Mental Health Act 1983 with a view to managing his behaviour with medication. The plan was to initiate this orally, but he refused, and so an intramuscular injection of 25 mg chlorpromazine was given to test his response to antipsychotic medication (which he had never had before). This was followed a week later by an injection of short-acting zuclopenthixol acetate (50 mg) and a week after that a depot injection of zuclopenthixol decanoate (50 mg). The depot was continued at monthly intervals. Over the next 2 months the disinhibited behaviours reduced, although he developed moderate extrapyramidal side-effects.
He was discharged on the depot on leave to a nursing home. However, despite being given full information about his legal status (which authorised the use of the depot even without his consent) and the reason for giving the depot, staff at the home did not feel able to administer it to him. The sexual behaviours began to return very intrusively. He repeatedly mutually masturbated a mentally incompetent female resident, who appeared to enjoy his attentions. The home found it difficult to discuss the situation with that persons husband. He touched and kissed other residents as well. He was moved to another wing, but managed to get back into the original wing.
When this became known he was recalled to hospital. A few weeks later he developed a chest infection, but refused treatment and died.
| Prevalence of hypersexuality |
|---|
|
|
|---|
Sourander & Sjogren (1970) studied 132 cases of Alzheimer s disease verified on post-mortem examination, reporting abnormal sexual behaviour in 17%. Rabins et al(1982) interviewed the caregivers of 55 people with dementia and found that only one family (2%) reported the occurrence of inappropriate sexual behaviour. Kumar et al(1988) compared questionnaire data relating to 28 people with Alzheimers disease and normal controls and found no significant difference in assaultative or sexually inappropriate behaviour (7% in both groups). Drachman et al(1992) reported hypersexual behaviour in 17% of out-patients with dementia and 8% of in-patients.
| Nature of hypersexuality in dementia |
|---|
|
|
|---|
There is no widely agreed definition of when a behaviour becomes abnormal, and so the decision is usually based either on a judgement of what is normal for a person in a particular situation (which is likely to be different according to whether they are in their own home, in a residential home or in hospital), or on the level of risk or discomfort to others. Little research has been carried out on the expression of sexuality in older people on which to base a judgement of what is normal, particularly in institutional settings, and it may be preferable to give greater attention to whether those involved experience the behaviour as distressing rather than whether it is normal.
Boxes 1
and 2
list major factors in the aetiology of changes in sexual behaviour in dementia.
Box 1 Why does sexual behaviour decrease in dementia?
|
| Box 2 Why does sexual behaviour increase in dementia? Disease-related factors
Social factors in inappropriate sexual behaviour
Psychological factors
Drugs
|
| Ethical issues |
|---|
|
|
|---|
Sexual behaviour can also present risks of harm or discomfort to those involved and their families, and people with dementia can themselves be very vulnerable to exploitation and distress. In deciding how to react to sexual behaviour, staff and institutions must consider the legal and ethical framework within which they work.
Box 3
summarises the assessment of competency. At both legal and ethical levels, the patients competence is central. If a patient in an institution is not competent to decide whether he or she wishes to proceed with a sexual contact, the staff have a duty of care towards him or her to ensure that no harm results. Whether it is ethical for a non-competent patient to take part in a sexual contact of any sort is a difficult decision which will need to be carefully considered in the light of the persons background and previous choices, and the nature of the contact. It will normally be helpful to discuss the situation with the patients family.
| Box 3 Assessment of competency to engage in a sexual relationship (after Lichtenberg & Strzepek, 1990) Patients awareness of the relationship
Can the patient avoid exploitation?
Is the patient aware of potential risks?
|
For a competent patient, the situation is ethically clearer in that the choice is primarily for the patient to make. Staff may have a role in supporting this decision (for example by ensuring access to private space). Attitudes of staff are very variable, and teams will need to discuss these issues explicitly to ensure that staff are adequately trained and supported. Barrett (2004) engagingly describes the difficulties that arose when an elderly non-demented man living in a residential home wished to pay for sexual services from female visitors.
| Assessment |
|---|
|
|
|---|
Since many of the interventions discussed below themselves carry risks, it is important to balance the risks presented by the behaviour against those of the intervention. Predisposing factors, physical, psychiatric and social need should also be reviewed.
Box 4
summarises the goals of assessment.
Box 4 Assessment of sexually disinhibited behaviour
|
| Management |
|---|
|
|
|---|
Box 5 Management of sexually disinhibited behaviour
|
| Behavioural treatments |
|---|
|
|
|---|
Providing staff with explanation, support and opportunities for discussion is extremely helpful. Holmes et al(1997) report a questionnaire survey of attitudes of professional carers in nursing homes towards sexuality in cognitively impaired residents. Most (7483%) staff supported the idea that sexual expression among residents with dementing illness is perfectly healthy and may contribute to their positive quality of life. About one-third of clinicians (33%) but almost two-thirds of administrators (61%, difference not significant) agreed that genital contact between residents with dementing illness should be discouraged. There was less agreement on behaviours such as hugging and kissing. Almost all staff agreed that staff training should be available.
Any behavioural approach needs to start with a careful assessment of the behaviour, followed by the development of a care plan agreed with staff and other interested parties such as the residents family. It is important to provide staff supervision. If these steps fail, it may be necessary to consider removal to another setting.
| Physical treatments |
|---|
|
|
|---|
|
Box 6 Classes of drugs used in managing sexually disinhibited behaviour
|
Neuroleptics
Neuroleptics are probably widely used in managing sexually disinhibited behaviour in dementia, but there is very little published evidence of their efficacy or safety in this group. Recent advice in the UK has emphasised the increased risk of cerebrovascular events in patients with dementia on olanzapine or risperidone. Benperidol has been used in the treatment of paraphilias (Field, 1973; British Medical Association & Royal Pharmaceutical Society of Great Britain, 2005). The availability of depot preparations can make their use possible with non-adherent patients, as in the case study that opened this article, provided that appropriate ethical and legal guidelines are followed.
Manipulation of testosterone levels
Anti-androgens, oestrogens and luteinising hormone releasing hormone (LHRH) agonists have been used in sexual offenders, but little is known about their use in older people with dementia. These agents decrease testosterone levels, which may reduce sexual drive (Schiavi & White, 1976). However, it is unclear how far serum testosterone correlates with hypersexual behaviour (Kravitz et al, 1996; Levitsky & Owens, 1999).
The secretion of testosterone is regulated by a feedback mechanism in the hypothalamuspituitarytestes axis. The hypothalamus produces gonadotrophin-releasing hormone, which stimulates the pituitary gland to produce luteinising hormone and follicle-stimulating hormone. Luteinising hormone stimulates the release of testosterone from the testes.
Circulating testosterone levels are maintained by a homoeostatic mechanism. When circulating testosterone levels decrease, an increase in production is promoted by luteinising hormone, which in turn is stimulated by LHRH. An increase in testosterone levels has an inhibitory effect on the hypothalamus and the pituitary.
Anti-androgens
The most widely used anti-androgens are medroxyprogesterone acetate (MPA) and cyproterone acetate (CPA).
Medroxyprogesterone acetate
This is a potent progestogen that decreases serum testosterone levels by inhibiting luteinising hormone release through negative feedback on hypothalamic receptors, hence reducing testosterone secretion from the testes as described above.
There are no controlled studies supporting the use of anti-androgens for the treatment of hyper-sexuality or paraphilias in older people with dementia (Levitsky & Owens, 1999). In two studies without controls, men with dementia were given intramuscular doses of 150300 mg MPA every 1 or 2 weeks; their inappropriate sexual behaviour stopped within 2 weeks (Cooper, 1987; Weiner et al, 1992). In a case report, marked disinhibited and disruptive sexual behaviour ceased in a man with dementia following intramuscular MPA treatment (Amadeo, 1996).
Cyproterone acetate
Another potent progestogen, CPA also possesses testosterone antagonistic activity by blocking androgen receptors.
Haussermann et al(2003) reported that administration of CPA to a man with vascular dementia and another with Parkinsons disease with associated dementia successfully reduced sexual acting out.
Cimetidine
Cimetidine is a histamine H2-receptor antagonist with non-hormonal anti-androgen properties in rats (Lardinois & Mazzaferri, 1985). It has been reported to decrease libido and hypersexual behaviour in 14 out of 20 patients with dementia without serious side-effects (Wiseman et al, 2000). The other six patients responded to combinations of cimetidine with ketoconazole, spironolactone or both, drugs that also exhibit anti-androgen action.
Oestrogens
Oestrogens (estrone, estradiol and diethylstilbestrol) have a strong negative feedback effect on hypothalamic and pituitary hormone secretion. They decrease luteinising hormone and follicle-stimulating hormone production, which leads to a reduction in the production of testosterone.
There are few reports on the use of oestrogens for the treatment of hypersexuality in people with dementia, possibly because of the greater presence of cardiovascular and thromboembolic risk factors in the older population and the association between cardiovascular-related deaths and oestrogen use in men treated with diethylstilbestrol for prostate cancer (Levitsky & Owens, 1999).
In one study, although few details are given, a marked improvement in sexual behaviour was seen in 38 out of 39 men with cognitive impairment when treated with oral oestrogen (0.625 mg/day) or with transdermal oestrogen patches (0.0050.1 mg) (Lothstein et al, 1997). In a case report, the hypersexual behaviour of a man with cognitive impairment stopped when he was given 1 mg diethylstilbestrol twice a day (Kyomen et al, 1991).
LHRH analogues
Gonadotrophin-releasing hormone (or gonadorelin agonists) are LHRH analogues. These reversibly suppress the pituitarygonadal axis by down-regulating the gonadotrophin cells. They stimulate the release of follicle-stimulating hormone and luteinising hormone from the pituitary, increasing androgen and oestrogen production. With continued administration of LHRH agonists, the pituitary no longer responds to endogenous LHRH, reducing the secretion of follicle-stimulating hormone and luteinising hormone, which causes a marked decrease in testosterone secretion. To remain effective, LHRH analogues have to be used on a continuous basis (Rosler & Witztum, 1998).
Leuprorelin, triptorelin and goserelin
These three LHRH analogues offer a treatment option for sex offenders and people with severe paraphilia (Briken et al, 2003). However, there is a case report of the use of leuprolide acetate (leuprorelin) to treat sexual aggression in a patient with dementia and KluverBucy syndrome (Ott, 1995), and Rich & Ovsiew (1994) report that it was effective in the treatment of exhibitionism in a patient with Huntingtons disease.
Serotonergics and noradrenergics
Selective serotonin reuptake inhibitors
Fluoxetine, paroxetine, citalopram and sertraline have been reported to be effective against sexual disinhibition and paraphilias (Greenberg et al, 1996). In addition to their antilibidinal effect, these drugs have anti-obsessive properties, tying in with the suggestion that hypersexuality and paraphilia might be related to obsessivecompulsive disorder (Perilstein et al, 1991; McElroy et al, 1994).
Stewart & Shin (1997) describe a reduction in sexual disinhibition in a patient with dementia when treated with paroxetine. A dramatic improvement in sexual aggression was also seen in a similar patient treated with citalopram (Raji et al, 2000).
The use of these agents may be attractive because of their relatively safe profile compared with other drugs.
Tricyclic antidepressants
Clomipramine, a tricyclic that inhibits the reuptake of serotonin and noradrenaline, was also effective in treating sexual disinhibition in two people with dementia (Leo & Kim, 1995). Careful monitoring of elderly people is required during treatment with clomipramine because of the risk of orthostasis, falls and worsened confusion.
Gabapentin
Gabapentin is an anti-epileptic structurally related to the central nervous system inhibitory neuro-transmitter gamma-aminobutyric acid (GABA). Gabapentin may increase GABA synthesis in the brain while decreasing the release of monoamine transmitters (Semanchuk & Labiner, 1997).
In Alzheimers disease, behavioural disturbances are associated with deficits of GABA in brain tissue (Hardy et al, 1987). Gabapentin has been successfully used for the management of agitation in Alzheimers disease (Regan & Gordon, 1997). It has also been reported to be effective in treating behavioural symptoms of dementia (Herrmann et al, 2000; Roane et al, 2000).
In a case report, a patient with vascular dementia showed reduced agitation and inappropriate sexual behaviour when treated with gabapentin (Miller, 2001). In three nursing home residents, two with Alzheimers disease and the other with vascular dementia, sexual disinhibition was effectively treated with gabapentin (Alkhalil et al, 2004).
Gabapentin is a relatively safe drug in elderly people.
Other drugs
Other psychotropic medications have been used to treat hypersexuality in people with dementia, with mixed results. Antimanic drugs (carbamazepine and valproic acid), often prescribed as adjuncts for behavioural symptoms of dementia, offer some effectiveness against disinhibition. Cholinesterase inhibitors, buspirone, propranolol, trazodone and benzodiazepines have also been tried (Lesser et al, 2005).
| MCQs |
|---|
|
|
|---|
MCQ answers
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Amadeo, M. (1996) Anti-androgen treatment of aggressivity in men suffering from dementia. Journal of Geriatric Psychiatry and Neurology, 9, 142145.
Barrett, J. (2004) Personal services or dangerous liaisons: should we help patients hire prostitutes? BMJ, 329, 985.
Briken, P., Hill, A. & Berner, W. (2003) Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. Journal of Clinical Psychiatry, 64, 890897.[Medline]
* British Medical Association & Royal Pharmaceutical Society of Great Britain (2005) British National Formulary (March issue). London & Wallingford: British Medical Association & Royal Pharmaceutical Society of Great Britain.
Burns, A., Jacoby, R. & Levy, R. (1990) Psychiatric phenomena in Alzheimer s disease. IV: Disorders of behaviour. British Journal of Psychiatry, 157, 8694.
Cooper, A. J. (1987) Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. Journal of Clinical Psychiatry, 48, 368370.[Medline]
Drachman, D. A., Swearer, J. M., ODonnell, B. F., et al (1992) The Caretaker Obstreperous Behavior Rating Assessment (COBRA) scale. Journal of the American Geriatrics Society, 40, 463480.[Medline]
eMC (2005) Electronic Medicines Compendium. http://emc.medicines.org.uk/
Field, L. H. (1973) Benperidol in the treatment of sex offenders. Medical Science and the Law, 13, 195.
Gijs, L. & Gooren, L. J. (1996) Hormonal and psychopharmacological interventions in the treatment of paraphilias: an update. Journal of Sex Research, 33, 273290.
Greenberg, D. M., Bradford, J. M. W., Curry, S., et al (1996) A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bulletin of the American Academy of Psychiatry and the Law, 24, 525532.
Grossman, L. S., Martis, B. & Fichtner, C. G. (1999) Are sex offenders treatable? A research overview. Psychiatric Services, 50, 349361.
Hardy J., Cowburn R., Barton A., et al (1987) A disorder of cortical gabaergic innervation in Alzheimer s disease. Neuroscience Letters, 73, 192196.[CrossRef][Medline]
Haussermann, P., Goecker, D., Beier, K., et al (2003) Low-dose cyproterone acetate treatment of sexual acting out in men with dementia. International Psychogeriatrics, 15, 181186.[CrossRef][Medline]
Herrmann, N., Lanctot, K. & Myszak, M. (2000) Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. Journal of Clinical Psychopharmacology, 20, 9093.[CrossRef][Medline]
Holmes, D., Reingold, J. & Teresi, J. (1997) Sexual expression and dementia. Views of caregivers: a pilot study. International Journal of Geriatric Psychiatry, 12, 695701.[CrossRef][Medline]
Kitwood, T. & Bredin, K. (1992) A new approach to the evaluation of dementia care. Journal of Advances in Health and Nursing Care, 1, 4160.
Kluver, H. & Bucy, P. (1937) "Psychic blindness" and other symptoms following bitemporal lobectomy in rhesus monkeys. American Journal of Physiology, 119, 352353.
Kravitz, H. M., Haywood, T. W., Kelly, J., et al (1996) Medroxyprogesterone and paraphiles: do testosterone levels matter? Bulletin of the American Academy of Psychiatry and the Law, 24, 7383.
Kumar, A., Koss, E., Metzler, D., et al (1988) Behavioral symptomatology in dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 2, 363365.[Medline]
Kyomen, H. H., Nobel, K. W. & Wei, J. Y. (1991) The use of estrogen to decrease aggressive physical behavior in elderly men with dementia. Journal of the American Geriatrics Society, 39, 11101112.[Medline]
Lardinois, C. K. & Mazzaferri, E. L. (1985) Cimetidine blocks testosterone synthesis. Archives of Internal Medicine, 145, 920922.[Abstract]
Leo, R. J. & Kim, K. Y. (1995) Clomipramine treatment of paraphilias in elderly demented patients. Journal of Geriatric Psychiatry and Neurology, 8, 123124.
Lesser, J. M., Hughes, S. V., Jemelka, J. R., et al (2005) Sexually inappropriate behaviors. Assessment necessitates careful medical and psychological evaluation and sensitivity. Geriatrics, 60, 34, 3637.
*Levitsky, A. M. & Owens, N. J. (1999) Pharmacologic treatment of hypersexuality and paraphilias in nursing home residents. Journal of the American Geriatrics Society, 47, 231234.[Medline]
Lishman, W. A. (1998) Organic Psychiatry: The Psychological Consequences of Cerebral Disorder (3rd edn). Oxford: Blackwell Science.
*Lichtenberg, P. A. & Strzepek, D. M. (1990) Assessments of institutionalized dementia patients competencies to participate in intimate relationships. Gerontologist, 30, 117120.[Abstract]
Lothstein, L. M., Fogg-Waberski, J. & Reynolds, P. (1997) Risk management and treatment of sexual disinhibition in geriatric patients. Connecticut Medicine, 61, 609618.[Medline]
McElroy, S. L., Phillips, K. A. & Keck, P. E., Jr. (1994) Obsessive compulsive spectrum disorder. Journal of Clinical Psychiatry, 55 (suppl.), 3351.
Miller, L. J. (2001) Gabapentin for treatment of behavioral and psychological symptoms of dementia. Annals of Pharmacotherapy, 35, 427431.[Abstract]
*Oppenheimer, C. (2002) Sexuality in old age. In Psychiatry in the Elderly (3rd edn) (eds R. Jacoby & C. Oppenheimer), pp. 837862. Oxford: Oxford University Press.
Ott, B. R. (1995) Leuprolide treatment of sexual aggression in a patient with dementia and the KluverBucy syndrome. Clinical Neuropharmacology, 18, 443447.[Medline]
Perilstein, R. D., Lipper, S. & Friedman, L. J. (1991) Three cases of paraphilias responsive to fluoxetine treatment. Journal of Clinical Psychiatry, 52, 169170.[Medline]
Rabins, R. V., Mace, N. L. & Lucas, M. J. (1982) The impact of dementia on the family. JAMA, 248, 333335.[CrossRef][Medline]
Raji, M., Liu, D. & Wallace, D. (2000) Case report. Sexual aggressiveness in a patient with dementia: sustained clinical response to citalopram. Annals of Long-Term Care, 8, 8183.
Regan, W. M. & Gordon, S. M. (1997) Gabapentin for behavioral agitation in Alzheimer s disease. Journal of Clinical Psychopharmacology, 17, 5960.[CrossRef][Medline]
Rich, S. S. & Ovsiew, F. (1994) Leuprolide acetate for exhibitionism in Huntingtons disease. Movement Disorders, 9, 353357.
Roane D. M., Feinberg T. E., Meckler L., et al (2000) Treatment of dementia-associated agitation with gabapentin. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 4043.
Rosler, A. & Witztum, E. (1998) Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. New England Journal of Medicine, 338, 416422.
Schiavi, R. C. & White, D. (1976) Androgens and male sexual function. A review of human studies. Journal of Sex and Marital Therapy, 2, 214228.
Semanchuk, M. R. & Labiner, D. M. (1997) Gabapentin and lamotrigine: prescribing guidelines for psychiatry. Journal of Practical Psychiatry and Behavioral Health, 3, 334342.
Sourander, P. & Sjogren, H. (1970) The concept of Alzheimers disease and its clinical implications. In Alzheimers Disease and Related Conditions (eds G. Wolstenholme & M. OConnor), pp. 1132. London: Churchill.
Stewart, J. T. & Shin, K. J. (1997) Paroxetine treatment of sexual disinhibition in dementia. American Journal of Psychiatry, 154, 1474.
Weiner, M. F., Denke, M., Williams, K., et al (1992) Intramuscular medroxyprogesterone acetate for sexual aggression in elderly men. Lancet, 339, 11211122.
Wells, A. (1997) Cognitive Therapy of Anxiety Disorders. Chichester: John Wiley & Sons.
Wiseman, S. V., McAuley, J. W., Freidenberg, G. R., et al (2000) Hypersexuality in patients with dementia: possible response to cimetidine. Neurology, 54, 2024.
Zeiss, A. M., Davies, H. D. & Tinklenberg, J. R. (1996) An observational study of sexual behavior in demented male patients. Journal of Gerontology, 51, M325M329.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| British Journal of Psychiatry | Psychiatric Bulletin | All RCPsych Journals |